Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties

Bioorganic and Medicinal Chemistry

Volumn 12, Issue 22, 2004, Pages 5865-5873

  Sriram, Dharmarajan ^a   Bal, Tanushree Ratan ^a   Yogeeswari, Perumal ^a  

^a BIRLA INSTITUTE OF TECHNOLOGY AND SCIENCE   (India)

Author keywords

Anti bacterial; Anti HCV; Anti HIV; Anti tuberculous; Isatin

Indexed keywords

1 ETHYL 6 FLUORO 1,4 DIHYDRO 4 OXO 7 [[N 4 [3' (4' AMINO 5' TRIMETHOXYBENZYLPYRIMIDIN 2' YL)IMINO 1' (5 FLUOROISATIN YL)]METHYL] N 1 PIPERAZINYL] 3 QUINOLINE CARBOXYLIC ACID; ANTIINFECTIVE AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIUM; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OPPORTUNISTIC INFECTION;

ANIMALS; ANTI-HIV AGENTS; ANTINEOPLASTIC AGENTS; CELL LINE; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MICE; REVERSE TRANSCRIPTASE INHIBITORS;

BACTERIA (MICROORGANISMS); HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MYCOBACTERIUM; MYCOBACTERIUM TUBERCULOSIS; UNIDENTIFIED RETROVIRUS;

EID: 6344240339     PISSN: 09680896     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmc.2004.08.028     Document Type: Article

References (19)

1. M.S. Gottlieb, R. Schroff, H.M. Schanker, J.D. Weisman, P.T. Fan, R.A. Wolf, and A. Saxon New Engl. J. Med. 305 1981 1425
2. F. Barre-Sinoussi, J.C. Chermann, F. Rey, M.T. Nugeyre, S. Chamaret, J. Gruest, C. Dauguet, C. Axler-Blin, F. Vezinet-Brun, C. Rouzioux, W. Rozenbaum, and L. Montagnier Science 220 1983 868
3. UNAIDS. AIDS Epidemic Update: 2003; WHO Library Cataloguing in-Publication Data: UNAIDS and WHO, 2003
4. D.L. Bowen, H.C. Hane, and A.C. Fauci Ann. Intern. Med. 163 1985 704
5. A. Di Bisceglie Lancet 351 1998 351
6. R.R. Rosado, P.M. Olmeda, G.J. Samaniego, and V. Soriano Antiviral Res. 52 2001 184
7. D. Sriram, and P. Yogeeswari Curr. Med. Chem. 10 2003 1909
8. E. De Clercq Farmaco 54 1999 26
9. E. De Clercq Med. Virol. 6 1996 97
10. Tripos Alchemy 2000, Alchemy 32 Version 2.0, Copyright 1997, Tripos Inc., St. Louis, MO, USA
11. S.N. Pandeya, D. Sriram, E. De Clercq, C. Pannecouque, and M. Witrouw Ind. J. Pharm. Sci. 60 1998 207
12. S.N. Pandeya, P. Yogeeswari, D. Sriram, E. De Clercq, C. Pannecouque, and M. Witrouw Chemotherapy 45 1999 192
13. J. Balzarini, P.M.J. Perez, S.A. Felix, M.J. Camarasa, I.C. Batharst, and P.J. Barr J. Biol. Chem. 267 1992 11831
14. C.A. Garcia, M. Micklatcher, J.A. Turpin, T.L. Stup, K. Watson, and R.W. Buckheit J. Med. Chem. 42 1999 4861
15. J.T. Guo, V.V. Bichkow, and C. Seeger J. Virol. 75 2002 8516
16. D. Sriram, K. Jyothimallika, and P. Yogeeswari Sci. Pharm. 72 2004 35
17. S.N. Pandeya, and D. Sriram Acta Pharm. Turc. 40 1998 33
18. S.N. Pandeya, D. Sriram, G. Nath, and E. De Clercq Eur. J. Med. Chem. 35 2000 249
19. A domestic microwave oven with the following specifications had been used: Make LG; input 220 V-50 Hz, 980 W, 4.7 A; frequency 2450 MHz